Details About Generic Salt ::  Bethanec

Main Medicine Class:: Urinary tract product, Cholinergic stimulant   

(beth-AN-ih-kole KLOR-ide)

Urecholine

Tablets: 5 mg, Tablets: 10 mg, Tablets: 25 mg, Tablets: 50 mg, Injection: 5 mg/mL, Duvoid, Tablets: 10 mg, Tablets: 25 mg, Tablets: 50 mg, Myotonachol, Tablets: 10 mg, Tablets: 25 mg, Myotonachol, Duvoid, PMS-Bethanechol Chloride, Urecholine

Class: Urinary tract product, Cholinergic stimulant

 

Drugs Class ::

 Action Stimulates parasympathetic nervous system, increasing tone to muscles of urinary bladder, stimulates gastric motility and tone and may restore rhythmic peristalsis.

Indications for Drugs ::

 Indications Treatment of acute postoperative and postpartum nonobstructive urinary retention and neurogenic atony of the urinary bladder with retention.

Diagnosis and treatment of reflux esophagitis.

Drug Dose ::

 Route/Dosage

ADULTS: PO 10 to 50 mg tid to qid on empty stomach. SC 2.5 to 5 mg at 15 to 30 min intervals for max of 4 doses; then minimum effective dose may be repeated tid to qid prn.

Contraindication ::

 Contraindications Hyperthyroidism; peptic ulcer; latent or active asthma; pronounced bradycardia; atrioventricular conduction defects; vasomotor instability; coronary artery disease; epilepsy; parkinsonism; coronary occlusion; hypotension; hypertension; bladder neck obstruction; spastic GI disturbances; acute inflammatory lesions of the GI tract; peritonitis; marked vagotonia. Not used when strength or integrity of GI or bladder wall is in question or in presence of mechanical obstruction, when increased muscular activity of GI tract or urinary tract may prove harmful (eg, after recent urinary bladder surgery, GI resection and anastomosis, possible GI obstruction).

Drug Precautions ::

 Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Reflux Infection: May occur if bethanechol administration fails to relax urinary sphincter and urine is forced back into renal pelvis. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic-type reactions (eg, bronchial asthma) in susceptible individuals.

PATIENT CARE CONSIDERATIONS

Drug Side Effects ::

 Adverse Reactions

CARDIOVASCULAR: Fall in BP with reflex tachycardia; vasomotor response. CNS: Headache. DERMATOLOGIC: Flushing with feeling of warmth; sensation of heat about face; sweating. EENT: Lacrimation; miosis. GI: Abdominal cramps or discomfort; colicky pain; nausea; belching; diarrhea; rumbling and gurgling of stomach; salivation. GU: Urinary urgency. RESPIRATORY: Bronchial constriction; asthmatic attacks. OTHER: Malaise.

Drug Mode of Action ::  

 Action Stimulates parasympathetic nervous system, increasing tone to muscles of urinary bladder, stimulates gastric motility and tone and may restore rhythmic peristalsis.

Drug Interactions ::

 Interactions Cholinergic Agents: Possible toxicity because of additive effects.

Ganglionic Blocking Compounds: Severe hypotension, usually preceded by severe abdominal symptoms.

Quinidine or Procainamide: Antagonism of anticholinergic effects of bethanechol.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies.
• Note any history of GI or urinary tract surgery or obstructions.
• Establish baseline BP and pulse and monitor BP, pulse, and voiding patterns. Notify health care provider if urinary retention persists.
• Report symptoms of asthma or bronchial constriction.

OVERDOSAGE: SIGNS & SYMPTOMS   Abdominal discomfort, salivation, flushing of skin, sweating, nausea, vomiting, low BP, shock, cardiac arrest

Drug Storage/Management ::

 Administration/Storage

• Give oral form on empty stomach.
• Use only SC route for parenteral administration. Violent symptoms of cholinergic overstimulation (eg, hypotension, circulatory collapse, cardiac arrest) may occur with IM or IV administration.
• Do not administer with quinidine or procainamide.

Drug Notes ::

 Patient/Family Education

• Caution patient about potential side effects such as increased salivation, sweating, flushing, or stomach discomfort.
• Instruct patient to take medication on empty stomach.
• Show patient how to monitor I&O, and to report abdominal distention or urinary retention to health care provider.
• Instruct patient to report the following symptoms to health care provider: abdominal pain or discomfort, diarrhea, visual disturbances, dizziness, any other disturbing response to medication.

–>

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.